Department of Orthopaedic, Shanxian Central Hospital, No 1, Wenhua Road, Shanxian, Heze City, 274300, Shandong Province, China.
Department of Orthopaedic, Shanxian Central Hospital, No 1, Wenhua Road, Shanxian, Heze City, 274300, Shandong Province, China.
Int J Surg. 2016 Dec;36(Pt A):127-137. doi: 10.1016/j.ijsu.2016.10.022. Epub 2016 Oct 20.
To evaluate the efficacy and safety of fibrin sealant for the reduction of postoperative blood loss and transfusion requirements in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA).
Electronic databases including PubMed, Embase, CENTRAL (Cochrane Controlled Trials Register), Web of Science and Google Scholar were searched from database inception to February 2016. All randomized controlled trials evaluating the efficacy and safety of topical administration of fibrin glue during primary THA or TKA were included in our meta-analysis. Transfusion requirements, total blood loss, length of hospital stay and the occurrence of infection were calculated using Stata 12.0 software.
A total of nineteen clinical trials with 1489 patients (405 hips and 1084 knees) were finally included for meta-analysis. The results indicated that the topical administration of fibrin sealant can decrease the need for transfusion (RR = 0.33, 95%CI 0.28-0.40, P < 0.001), total blood loss (MD = -138.25, 95% CI -203.49 to -75.00), blood loss in drainage (MD -321.44, 95% CI -351.96 to -290.92, P < 0.001) and hospital stay length (MD -0.98, 95% CI -1.35 to -0.62, P < 0.001) without increasing the occurrence of infection (RR = 0.87, 95% CI 0.33 to 2.27, P = 0.775).
The topical use of fibrin sealant can effectively reduce the need for transfusion, total blood loss and the volume of drainage without increasing the rate of infection.
评估纤维蛋白胶在全髋关节置换术(THA)和全膝关节置换术(TKA)中减少术后失血和输血需求的疗效和安全性。
计算机检索 PubMed、Embase、CENTRAL(Cochrane 对照试验注册库)、Web of Science 和 Google Scholar 等电子数据库,检索时限均从建库至 2016 年 2 月。纳入所有评估原发性 THA 或 TKA 术中局部应用纤维蛋白胶的疗效和安全性的随机对照试验。采用 Stata12.0 软件计算输血需求、总失血量、住院时间和感染发生率。
共纳入 19 项临床试验,共计 1489 例患者(405 髋和 1084 膝),最终纳入 meta 分析。结果表明,局部应用纤维蛋白胶可减少输血需求(RR=0.33,95%CI 0.28-0.40,P<0.001)、总失血量(MD=-138.25,95%CI-203.49 至-75.00)、引流血丢失量(MD=-321.44,95%CI-351.96 至-290.92,P<0.001)和住院时间长度(MD=-0.98,95%CI-1.35 至-0.62,P<0.001),而不增加感染发生率(RR=0.87,95%CI 0.33 至 2.27,P=0.775)。
局部应用纤维蛋白胶可有效减少输血需求、总失血量和引流血量,而不增加感染率。